Health & Fitness
Health and Fitness
Health and Fitness
Fri, January 9, 2009
Thu, January 8, 2009 Vicor Technologies, Inc.: Vicor Technologies Announces Receipt of Eurasian Patent for Its Altered State Physiology Drug Develop
BOCA RATON, FL--(Marketwire - January 8, 2009) - David H. Fater, president and CEO of Vicor Technologies, Inc., today announced that on December 31, 2008, Vicor received Eurasian Patent (010860) for its altered state physiology drug development platform. Vicor Technologies, Inc. (
Vicor's altered state physiology drug development platform is based on the clinical peptides and proteins derived from "state-dependent" physiologies. This platform may be used to advance the treatment of an array of human conditions, including stroke ischemia, cardiac ischemia, kidney failure, hypertension, obesity, cancer, and organ transplant/preservation, by reducing the cost, time, and risk associated with bringing related pharmaceuticals to market. The Eurasian Patent (010860) is valid for 20 years through December 31, 2028 in all of the contracting states: Armenia, Azerbaijan, Belarus, Kirgizstan, Kazakhstan, Moldova, Russia, Tajikistan, and Turkmenistan.
"This is the second international patent we've received for our drug development platform in its entirety and we're hopeful that we'll receive notice from the U.S. patent office some time this year," stated Mr. Fater. "We believe our drug development platform has significant advantages over the drug development process currently in use, which focuses on the time- and cost-intensive testing of compounds on nerve receptors and genes. Additionally, as these peptides and proteins are naturally occurring in mammals, there is a high probability of non-toxicity; toxicity is a significant issue in the current testing process," Mr. Fater concluded.
About Vicor Technologies, Inc.
Vicor is a development-stage biotechnology company focused on the commercialization of innovative non-invasive diagnostics employing operational software and its patented, proprietary PD2i algorithm, a deterministic, non-linear analytic measure that accurately evaluates electrophysiological potentials with high sensitivity and high specificity to predict future pathological events in target populations.
Vicor currently has three products employing the PD2i algorithm. The PD2i Analyzer, which has received FDA 510(k) approval, measures heart rate variability. The PD2i VS (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research ([ http://www.usaisr.amedd.army.mil/ ]), risk stratifies combat and civilian trauma victims. FDA 510(k) approval to market the PD2i VS is expected in 2009. The PD2i CA (Cardiac Analyzer), in a multi-site, multi-year trial (the VITAL Trial) being conducted by the Harvard Clinical Research Institute, identifies patients at risk of suffering sudden cardiac death. FDA 510(k) approval to market the PD2i CA is expected in early 2010.
Vicor anticipates developing additional applications using the PD2i to enable early detection and risk stratification for a variety of other disorders and diseases.
Vicor is also engaged in the pre-clinical and early clinical development of specific occurring peptides and proteins derived from "state-dependent" physiologies to advance the treatment of an array of human conditions -- e.g., stroke ischemia, cardiac ischemia, kidney failure, hypertension, obesity, and cancer, organ transplant/preservation -- by reducing the cost, time, and risk associated with bringing potential products to market.
Additional information is available at [ www.vicortech.com ].
The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein.
Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to obtain FDA approval of the PD2i VS for military and civilian applications and the PD2i Cardiac Analyzer, our ability continue to receive financing sufficient to continue operations and complete the critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.
Release 09-03
